Nuvation Bio Stock
Nuvation Bio Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David T. Hung
- Employees
- 305
- Market cap
- $1.6 B
- IPO
- 26/08/2020
Nuvation Bio Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the discovery and advancement of therapeutic solutions for oncological conditions. Headquartered in New York City, USA, the company is led by CEO David T. Hung. The development pipeline features several experimental compounds, including…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Nuvation Bio stock: price history
1D
-6.3%
1W
-11.0%
1M
-23.0%
6M
-12.4%
YTD
-50.3%
1Y
+22.6%
2Y
+73.2%
5Y
-53.4%
10Y
–
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~31% stronger price swings than usual
Ask the agents about Nuvation Bio
Analyst assessment of Nuvation Bio
PRICE TARGET LOW
US$20.00
CONSENSUS
US$20.50
MEDIAN
US$20.50
PRICE TARGET HIGH
US$21.00
0
STRONG BUY
8
BUY
2
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 16/09/2026
Nuvation Bio stock metrics
P/E
-10.24
P/B
6.11
EV/EBITDA
-12.21
RETURN ON EQUITY
-24.8%
NET MARGIN
-198.3%
DEBT/EQUITY
0.99
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.0%
FLOAT SHARES
251,976,047
AVG. DAILY VOLUME (30D)
5,380,716
Insider transactions (SEC)
Hattersley Gary
Hattersley Gary
Sauvage Philippe
Sauvage Philippe
Wentworth Kerry
Institutional holders
Comparable stocks
Frequently asked questions about Nuvation Bio stock
What does Nuvation Bio do?
Nuvation Bio Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David T. Hung, the company employs around 305 people.
The IPO was on 26/08/2020; the stock trades on NYSE under the ticker NUVB.
What do analysts say about Nuvation Bio stock?
10 analysts rate the stock, the consensus is Buy (as of 16/09/2026).
The average price target is US$20.50, ranging from US$20.00 to US$21.00, with a median of US$20.50.
This is an external assessment, not a statement by Market Jury.
When does Nuvation Bio report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 31% stronger than usual.
Does Nuvation Bio pay a dividend?
No, Nuvation Bio currently does not pay a dividend.
Which stocks are comparable to Nuvation Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Nuvation Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nuvation Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.